Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 505-510

  Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Acute coronary syndromes; Anticoagulant therapy; Antiplatelet therapy; Atrial fibrillation; Hemophilia A; Hemophilia B

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; WARFARIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTIFICIAL EMBOLISM; BARE METAL STENT; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; DRUG COST; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUBSTITUTION THERAPY; THROMBOGENESIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ATRIAL FIBRILLATION; DISEASE MANAGEMENT; FIBRINOLYTIC AGENTS; HEMOPHILIA A; HUMANS;

EID: 84857245676     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.656591     Document Type: Review

References (21)

1. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008;14:10-18 (Pubitemid 351722377)
2. Rosendaal FR, Briet E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990;75:525-30 (Pubitemid 20271483)
3. Plug I, Van der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006;4:510-16
4. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-42 (Pubitemid 30463360)
5. Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. Haemophilia 2003;9:703-10 (Pubitemid 37547903)
6. Siboni SM, Mannucci PM, Gringeri A, et al. Health status and quality of life of elderly persons with severe haemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009;7:780-6
7. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35
8. Wallny TA, Scholz DT, Oldenburg J, et al. Osteoporosis in haemophilia - an underestimated comorbidity? Haemophilia 2007;13:79-84 (Pubitemid 46002349)
9. Hofstede FG, Fijnvandraat K, Plug I, et al. Obesity: a new disaster for haemophilic patients? A nationwide survey. Haemophilia 2008;14:1035-8
10. Girolami A, Ruzzon E, Fabris F, et al. Myocardial infarction and other arterial occlusions in hemophilia A patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006;116:120-5 (Pubitemid 44252768)
11. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, et al. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009;7:247-54
12. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009;114:5256-63
13. Mannucci PM, Mauser-Bunschoten EP. Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia 2010;16(S3):58-66
14. Hirsh J, Guyatt G, Albers GW, et al. American College of Chest Physician. Antithrombotic and thrombolytic therapy: American College of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133(S6):110S-2S (Pubitemid 351892962)
15. Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators. Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503 (Pubitemid 47212371)
16. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(S6):546S-92S (Pubitemid 351892972)
17. Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull 2008;88:75-94
18. Shelton RJ, Clark AL, Goode K. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-30
19. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results of the national registry of atrial fibrillation. JAMA 2001;285:2864-70 (Pubitemid 32537350)
20. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
21. Mannucci PM, Nobili A, Garattini S. New drugs for thromboprophylaxis in atrial fibrillation. Eur J Intern Med 2012;23:1-5.